FDA bans suck sales out of Ranbaxy, Wockhardt

Eric Palmer

Import imposed against two of India's largest generic drugmakers are already shaving away their financial performance, even though the worst is yet to come. Both Laboratories and today reported diminished results, with Ranbaxy being pummeled hard by a variety of factors, including the ban.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS